BioNexus Gene Lab Corp Quarterly Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest in USD from Q2 2021 to Q2 2024
-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
-
Summary
-
BioNexus Gene Lab Corp quarterly/annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest history and growth rate from Q2 2021 to Q2 2024.
- BioNexus Gene Lab Corp Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the quarter ending June 30, 2024 was $255K.
- BioNexus Gene Lab Corp Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the twelve months ending June 30, 2024 was -$2.11M, a 303% decline year-over-year.
- BioNexus Gene Lab Corp annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2023 was -$2.61M, a 759% decline from 2022.
- BioNexus Gene Lab Corp annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2022 was -$304K, a 129% decline from 2021.
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Trailing 12 Months (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Quarterly (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Quarterly Growth (%)